Search research articles
Contact Us
Filters
Showing results (41-50 of 97) with videos related to
Page
of 10
Sort By:
Clinical Biochemistry
|
February 26, 2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease
Helena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Blood Pressure
|
October 14, 2023
The Hypertension Excellence Centre programme of the European Society of Hypertension - current status, activities and reshaping for the future
Thomas Weber, Michael Doumas, Christian Delles, et al.
Molecular and Cellular Biochemistry
|
June 8, 2011
Cholesterol-rich low density lipoproteins are also more oxidized
Vadim Lankin, Margus Viigimaa, Alla Tikhaze, et al.
Cardiovascular Therapeutics
|
July 15, 2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Helena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Journal of Diabetes
|
May 21, 2015
Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients
Vadim Z Lankin, Galina G Konovalova, Alla K Tikhaze, et al.
Diabetes & Vascular Disease Research
|
August 24, 2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Helena Vaverkova, et al.
Archives of Medical Science : AMS
|
December 2, 2022
2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy
Maciej Banach, Zeljko Reiner, Arrigo F G Cicero, et al.
BMC Medical Genetics
|
January 30, 2010
Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits
Katrin Kepp, Elin Org, Siim Sõber, et al.
European Heart Journal
|
November 5, 2010
Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study
Guido Grassi, Renata Cifkova, Stephane Laurent, et al.
BMJ Open
|
May 27, 2026
Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention: study protocol for the EE-PRS trial
Ave Voit, Aet Elken, Margus Viigimaa, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 97) with videos related to
Sort By:
Page
of 10
Clinical Biochemistry
|
February 26, 2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease
Helena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Blood Pressure
|
October 14, 2023
The Hypertension Excellence Centre programme of the European Society of Hypertension - current status, activities and reshaping for the future
Thomas Weber, Michael Doumas, Christian Delles, et al.
Molecular and Cellular Biochemistry
|
June 8, 2011
Cholesterol-rich low density lipoproteins are also more oxidized
Vadim Lankin, Margus Viigimaa, Alla Tikhaze, et al.
Cardiovascular Therapeutics
|
July 15, 2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Helena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Journal of Diabetes
|
May 21, 2015
Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients
Vadim Z Lankin, Galina G Konovalova, Alla K Tikhaze, et al.
Diabetes & Vascular Disease Research
|
August 24, 2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Helena Vaverkova, et al.
Archives of Medical Science : AMS
|
December 2, 2022
2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy
Maciej Banach, Zeljko Reiner, Arrigo F G Cicero, et al.
BMC Medical Genetics
|
January 30, 2010
Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits
Katrin Kepp, Elin Org, Siim Sõber, et al.
European Heart Journal
|
November 5, 2010
Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study
Guido Grassi, Renata Cifkova, Stephane Laurent, et al.
BMJ Open
|
May 27, 2026
Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention: study protocol for the EE-PRS trial
Ave Voit, Aet Elken, Margus Viigimaa, et al.
Page
of 10